After a 1 week run-in period CASAD will be administered TID for 1 week. Each dose will be 2 500mg CASAD capsules. Patients will be followed for two weeks post active drug administration.

Diarrhea

Medullary Thyroid Cancer

CASAD

MD Anderson Cancer Center

The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer

To evaluate the efficacy of CASAD 3 grams per day in reducing the severity of diarrhea after 1 week of treatment in patients with MTC.

To explore the functional impact of CASAD and the relative impact of diarrhea in relation to other symptom issues using MDASI-THY (M.D. Anderson Symptom Inventory-Thyroid, appendix D)

To explore the effect of CASAD on thyroid function tests, thyroid hormone and calcium absorption

To examine changes in MDASI-THY scores after treatment with CASAD

Salient Pharmaceuticals Incorporated

Neuroendocrine Tumors

Patients will receive 200mCi dose of 177Lu Dotatate

177Lu-DOTATATE

Excel Diagnostics and Nuclear Oncology Center

177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

Overall response will be determined by Progression Free Survival (PFS). PFS will be calculated as a function of time from start of therapy to time of overall disease progression. Patients will be censored at the date of last contact

Patients will be monitored for dose toxicity according to NCI guidelines

Ebrahim S. Delpassand

Chairman and Medical Director

Radio Isotope Therapy of America

Vandetanib administered as a once daily dose, continuously (1 cycle = 28 days) at a dose of 150 mg/m2/d.

Medullary Thyroid Carcinoma

Multiple Endocrine Neoplasia Type 2A

Multiple Endocrine Neoplasia Type 2B

Vandetanib

National Institutes of Health Clinical Center, 9000 Rockville Pike

Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer

Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma

National Cancer Institute (NCI)

Sunitinib will be administered orally daily for 4 weeks followed by a 2-week rest; the daily starting dose will be 50 mg with a provision for dose reduction based on tolerability. All patients will receive repeated cycles until disease progression or occurrence of severe toxicity.

Cancer

Thyroid Carcinoma

Capsule, 12.5 or 50 mg, starting dose level 50 mg daily

thyroid neoplasms/ripuli

The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer

177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer

Thyroid Cancer and Sunitinib

Täydellisin lääketieteellinen tietokanta tieteen tukemana